NCT03864601View on ClinicalTrials.gov

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

June 14, 2019

Study Completion Date

June 14, 2019

Conditions
Healthy
Interventions
DRUG

14C-JNJ-56136379

14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03864601 - A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants | Biotech Hunter | Biotech Hunter